Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment

被引:689
作者
Budhu, Anuradha
Forgues, Marshonna
Ye, Qing-Hai
Jia, Hu-Liong
He, Ping
Zanetti, Krista A.
Kammula, Udai S.
Chen, Yidong
Qin, Lun-Xiu
Tang, Zhao-You [1 ]
Wang, Xin Wei
机构
[1] NCI, Liver Carcinogenesis Sect, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China
[4] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Bethesda, MD 20892 USA
[5] NCI, Mol Genet & Carcinogenesis Sect, Human Carcinogenesis Lab, Bethesda, MD 20892 USA
[6] NCI, Canc Prevent Fellowship Program, Div Canc Prevent, Bethesda, MD 20892 USA
[7] Natl Human Genome Res Inst, Canc Genet Lab, Bethesda, MD 20892 USA
[8] NCI, Surg Branch, Bethesda, MD 20892 USA
关键词
D O I
10.1016/j.ccr.2006.06.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is an aggressive malignancy mainly due to metastases or postsurgical recurrence. We postulate that metastases are influenced by the liver microenvironment. Here, we show that a unique inflammation/immune response-related signature is associated with noncancerous hepatic tissues from metastatic HCC patients. This signature is principally different from that of the tumor. A global Th1/Th2-like cytokine shift in the venous metastasis-associated liver microenvironment coincides with elevated expression of macrophage colony-stimulating factor (CSF1). Moreover, a refined 17 gene signature was validated as a superior predictor of HCC venous metastases in an independent cohort, when compared to other clinical prognostic parameters. We suggest that a predominant humoral cytokine profile occurs in the metastatic liver milieu and that a shift toward anti-inflammatory/immune-suppressive responses may promote HCC metastases.
引用
收藏
页码:99 / 111
页数:13
相关论文
共 41 条
  • [1] P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells
    Ambs, S
    Merriam, WG
    Ogunfusika, MO
    Bennett, WP
    Ishibe, N
    Hussain, SP
    Tzeng, EE
    Geller, DA
    Billiar, TR
    Harris, CC
    [J]. NATURE MEDICINE, 1998, 4 (12) : 1371 - 1376
  • [2] Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer
    Berghella, AM
    Contasta, I
    Pellegrini, P
    Del Beato, T
    Adorno, D
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2002, 17 (01) : 43 - 50
  • [3] Metastasis genes: A progression puzzle
    Bernards, R
    Weinberg, RA
    [J]. NATURE, 2002, 418 (6900) : 823 - 823
  • [4] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [5] Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma
    D'Arrigo, A
    Belluco, C
    Ambrosi, A
    Digito, M
    Esposito, G
    Bertola, A
    Fabris, M
    Nofrate, V
    Mammano, E
    Leon, A
    Nitti, D
    Lise, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (02) : 256 - 262
  • [6] Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Dave, SS
    Wright, G
    Tan, B
    Rosenwald, A
    Gascoyne, RD
    Chan, WC
    Fisher, RI
    Braziel, RM
    Rimsza, LM
    Grogan, TM
    Miller, TP
    LeBlanc, M
    Greiner, TC
    Weisenburger, DD
    Lynch, JC
    Vose, J
    Armitage, JO
    Smeland, EB
    Kvaloy, S
    Holte, H
    Delabie, J
    Connors, JM
    Lansdorp, PM
    Ouyang, Q
    Lister, TA
    Davies, AJ
    Norton, AJ
    Muller-Hermelink, HK
    Ott, G
    Campo, E
    Montserrat, E
    Wilson, WH
    Jaffe, ES
    Simon, R
    Yang, LM
    Powell, J
    Zhao, H
    Goldschmidt, N
    Chiorazzi, M
    Staudt, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21) : 2159 - 2169
  • [7] The interplay between innate and adaptive immunity regulates cancer development
    de Visser, KE
    Coussens, LM
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) : 1143 - 1152
  • [8] Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population
    Fidler, IJ
    Kripke, ML
    [J]. NATURE GENETICS, 2003, 34 (01) : 23 - 23
  • [9] MODULATION OF THE ORGAN MICROENVIRONMENT FOR TREATMENT OF CANCER METASTASIS
    FIDLER, IJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) : 1588 - 1592
  • [10] Natural killer cells: Primary target for hepatitis C virus immune evasion strategies?
    Golden-Mason, L
    Rosen, HR
    [J]. LIVER TRANSPLANTATION, 2006, 12 (03) : 363 - 372